Vancomycin

Generic Name: Vancomycin

Brand Names: Firvanq, Vancocin

Drug Type: Small Molecule

Chemical Formula: C_₆₆H_₇₅Cl_₂N_₉O_₂₄

CAS Number: 1404-90-6

Unique Ingredient Identifier: 6Q205EH1VU

Background: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].

Indication: Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

Associated Conditions: Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection

Associated Therapies: -

Clinical Trials

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: Fluconazole
Drug: Vancomycin
Drug: Neomycin
Drug: Ciprofloxacin
Drug: Polyethylene Glycol 3350
Drug: Fluconazole placebo
Drug: Promethazine

First Posted Date: 2016-05-06

Last Posted Date: 2024-02-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 8

Registration Number: NCT02765256

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection

Phase 3

Completed

Conditions: Clostridium Difficile Infection

Interventions: Other: Fecal microbiota transplantation
Drug: Fidaxomicin
Drug: Vancomycin

First Posted Date: 2016-04-19

Last Posted Date: 2019-10-15

Lead Sponsor: University of Aarhus

Target Recruit Count: 64

Registration Number: NCT02743234

Locations: 🇩🇰
Aarhus University Hospital, Aarhus C, Denmark

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Phase 2

Terminated

Conditions: Neoplasms
Febrile Neutropenia

Interventions: Drug: CAZ-AVI
Drug: Vancomycin
Drug: Linezolid
Drug: Cefepime
Drug: Meropenem
Drug: Piperacillin/tazobactam

First Posted Date: 2016-04-08

Last Posted Date: 2017-07-21

Lead Sponsor: Forest Laboratories

Target Recruit Count: 2

Registration Number: NCT02732327

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Interventional Bioremediation of Microbiota in Metabolic Syndrome

Phase 2

Terminated

Conditions: Pre-Diabetes

Interventions: Other: Placebo
Drug: Vancomycin
Drug: Neomycin
Drug: Clindamycin
Procedure: Fecal Microbiota Transplantation

First Posted Date: 2016-04-07

Last Posted Date: 2023-02-22

Lead Sponsor: University of Minnesota

Target Recruit Count: 12

Registration Number: NCT02730962

Locations: 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

Phase 4

Completed

Conditions: Clostridium Difficile Infection (CDI)

Interventions: Drug: Fidaxomicin
Drug: Vancomycin

First Posted Date: 2016-02-26

Last Posted Date: 2022-03-25

Lead Sponsor: University of Michigan

Target Recruit Count: 144

Registration Number: NCT02692651

Locations: 🇺🇸
St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection

Phase 2

Conditions: Clostridium Difficile Infection

Interventions: Biological: Fecal Microbiota
Drug: vancomycin
Drug: Loperamide
Drug: metronidazole

First Posted Date: 2016-02-19

Last Posted Date: 2016-09-27

Lead Sponsor: Queen Elizabeth II Health Sciences Centre

Target Recruit Count: 50

Registration Number: NCT02686645

Optimal Treatment for Recurrent Clostridium Difficile

Phase 4

Completed

Conditions: Difficile
Fidaxomicin
Vancomycin
Clostridium

Interventions: Drug: Fidaxomicin
Drug: Vancomycin
Drug: Vancomycin with Taper/Pulse

First Posted Date: 2016-01-28

Last Posted Date: 2024-10-04

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 308

Registration Number: NCT02667418

Locations: 🇺🇸
Southern Arizona VA Health Care System, Tucson, AZ, Tucson, Arizona, United States
🇺🇸
VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
🇺🇸
Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, United States

and more 29 locations